LETTER

Role of CIq/TNF-Related Protein 6 for the Evaluation of Coronary Heart Disease Associated with Type 2 Diabetes [Letter]

Imam Sarwo Edi¹, Sari Luthfiyah (1)², Triwiyanto Triwiyanto³, Bedjo Utomo (1)³

Department of Dental Health, Poltekkes Kemenkes Surabaya, Surabaya, Indonesia; Department of Nursing, Poltekkes Kemenkes Surabaya, Surabaya, Indonesia; ³Department of Medical Electronics Technology, Poltekkes Kemenkes Surabaya, Surabaya, Indonesia

Correspondence: Sari Luthfiyah, Email sarilut@poltekkesdepkes-sby.ac.id

Dear editor

We would like to take this opportunity to express our appreciation for the authors of the recent study on the role of C1q/ TNF-Related Protein 6 (CTRP6) in evaluating coronary heart disease associated with Type 2 Diabetes. The results presented in the paper provide insight into the potential significance of CTRP6 as a biomarker for assessing cardiovascular risk in patients with Type 2 Diabetes. The results of the correlation analysis revealed a number of significant relationships between CTRP6 levels and various clinical and laboratory parameters. These findings offer valuable insights into the pathophysiology of coronary heart disease in this population.

It should be noted that the findings of this study must be considered within the context of several limitations and weaknesses. The sample size of the study (160 participants) may appear relatively small. In order to enhance the generalisability of the results and ensure the reliability of the conclusions, it would be beneficial to recruit a larger and more diverse cohort of subjects.

Moreover, while the correlation analysis indicated statistically significant associations, further mechanistic studies are necessary to elucidate the precise role of CTRP6 in the pathogenesis and progression of coronary heart disease in patients with Type 2 Diabetes Mellitus. Addressing the aforementioned limitations would enhance the reliability and significance of the findings. The sample size of 160 subjects may be relatively small, and the study design could benefit from a larger and more diverse cohort to enhance the generalizability of the results.² Furthermore, while the correlation analysis indicated significant correlations,³ additional mechanistic studies are required to elucidate the precise role of CTRP6 in the development and progression of coronary heart disease in Type 2 Diabetes mellitus patients. Addressing these limitations could strengthen the validity and impact of the findings.

Moving forward, we recommend that future research in this area focuses on longitudinal studies to establish a causal relationship between CTRP6 levels and cardiovascular outcomes in Type 2 Diabetes patients. Furthermore, the potential therapeutic implications of modulating CTRP6 levels for the prevention and management of coronary heart disease could pave the way for the development of novel treatment strategies. The integration of clinical, research, and industry expertise may facilitate the translation of these research findings into clinical practice, ultimately improving patient care and outcomes in this high-risk population.⁵

We would like to express our gratitude for your consideration of our feedback on this significant research study. It is our contention that addressing these points will not only enhance our understanding of the role of CTRP6 in coronary heart disease associated with type 2 diabetes, but also contribute to the development of personalised and effective interventions for patients at risk of cardiovascular complications.

Disclosure

The authors report no conflicts of interest in this communication.

Edi et al Dovepress

References

1. Li M, Zhou S, Feng Z, et al. Therapeutics and Clinical Risk Management Role of C1q/TNF-Related Protein 6 for the Evaluation of Coronary Heart Disease Associated with Type 2 Diabetes Role of C1q / TNF-Related Protein 6 for the Evaluation of Coronary Heart Disease Associated with Type. Therapeutics Clin Risk Manag. 2024:289. doi:10.2147/TCRM.S464007

- 2. Wang X, Kattan MW. Cohort Studies: design, Analysis, and Reporting. Chest. 2020;158(1):S72-S78. doi:10.1016/j.chest.2020.03.014
- 3. Sapra R, Saluja S. Understanding statistical association and correlation. Curr Med Res Pract. 2021;11(1):31. doi:10.4103/cmrp.cmrp_62_20
- 4. Tuthill EL, Maltby AE, DiClemente K, Pellowski JA. Longitudinal Qualitative Methods in Health Behavior and Nursing Research: assumptions, Design, Analysis and Lessons Learned. Int J Qual Methods. 2020;19:1-28. doi:10.1177/1609406920965799
- 5. Kagan J, Lassa J, Zuckerman J, et al. Strategy management in collaborative clinical research partnerships. Contemp Clin Trials Commun. 2021;24:100833. doi:10.1016/j.conctc.2021.100833

Dove Medical Press encourages responsible, free and frank academic debate. The contentTxt of the Therapeutics and Clinical Risk Management 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Therapeutics and Clinical Risk Management editors. While all reasonable steps have been taken to confirm the contentTxt of each letter, Dove Medical Press accepts no liability in respect of the contentTxt of any letter, nor is it responsible for the contentTxt and accuracy of any letter to the editor.

Therapeutics and Clinical Risk Management

Dovepress

Publish your work in this journal

Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines. This journal is indexed on PubMed Central, CAS, EMBase, Scopus and the Elsevier Bibliographic databases. The management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.downerses.com/testimonicle.php to read real guetes from published authors. dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/therapeutics-and-clinical-risk-management-journal